Pfenex Inc. (NYSEMKT:PFNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Principal Officers; Compensatory
Arrangements of Certain Officers.
As noted below, on May5, 2017, our stockholders approved the
amendment and restatement of our 2014 Equity Incentive Plan (1)to
amend and restate the material terms of the plan to allow us the
ability to deduct in full under Section 162(m) of the Internal
Revenue Code of 1986, as amended, compensation recognized by our
executive officers in connection with certain awards that may be
granted under the plan in the future; (2)to increase the number
of shares of common stock reserved thereunder by 2,500,000
shares; and (3)to make such other changes as described in the
proxy statement. The Amended and Restated 2014 Equity Incentive
Plan is described in more detail in the Companys 2017 Proxy
Statement, which was filed with the Securities and Exchange
Commission on April3, 2017. The foregoing description and the
summary contained in the Companys 2017 Proxy Statement do not
purport to be complete and are qualified in their entirety by
reference to the full text of the Amended and Restated 2014
Equity Incentive Plan, which is attached hereto as Exhibit 10.1.
Item5.07 Submission of Matters to a Vote of Security
Holders.
We held our 2017 annual meeting of stockholders on May5, 2017
(the Annual Meeting). Of the 23,443,352 shares of our common
stock outstanding as the record date of March10, 2017, 19,702,216
shares were represented at the Annual Meeting, either in person
or by proxy, constituting approximately 84% of the outstanding
shares of common stock. The matters voted on at the Annual
Meeting and the votes cast with respect to each such matter are
set forth below:
| 1. |
Election of ClassIII Directors. Each of the following nominees was elected to serve as a ClassIII director, to hold office until our 2020 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his earlier resignation or removal based on the following results of voting: |
|
Nominee |
Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
Jason Grenfell-Gardner |
16,376,262 | 403,560 | 2,922,394 | |||||||||
|
Sigurdur Olafsson |
16,378,286 | 401,536 | 2,922,394 |
| 2. |
Approval of Amended and Restated 2014 Equity Incentive Plan. The amendment and restatement of the Companys 2014 Equity Incentive Plan was approved, including (1)the amendment and restatement of the material terms of the plan to allow the Company the ability to deduct in full under Section 162(m) of the Internal Revenue Code of 1986, as amended, compensation recognized by the Companys executive officers in connection with certain awards that may be granted under the plan in the future; (2)an increase in the number of shares of common stock reserved thereunder by 2,500,000 shares; and (3)such other changes as described in the Proxy Statement. |
|
Votes For |
VotesAgainst | Abstentions | BrokerNon-Votes | |||||||||||
| 13,501,410 | 3,272,486 | 5,926 | 2,922,394 |
| 3. |
Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December31, 2017 was ratified based on the following results of voting: |
|
Votes For |
VotesAgainst | Abstentions | BrokerNon-Votes | |||||||||||
| 19,629,946 | 59,560 | 12,710 |
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
| 10.1 |
Amended and Restated 2014 Equity Incentive Plan and forms of award thereunder. |
About Pfenex Inc. (NYSEMKT:PFNX)
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection. Pfenex Inc. (NYSEMKT:PFNX) Recent Trading Information
Pfenex Inc. (NYSEMKT:PFNX) closed its last trading session up +0.16 at 5.08 with 70,740 shares trading hands.
